cell signalling technology 8707 Search Results


rabbit map2  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc rabbit map2
a, Representative immunofluorescence images showing increased VGLUT1 intensity in the hippocampus of 3xTg mice 15 days after intrahippocampal injection with TREK1 shRNA lentivirus compared with vehicle-injected controls. b, Representative images showing decreased VGAT intensity under the same TREK1 knockdown conditions. c, Quantification of VGLUT1 fluorescence intensity in 3xTg mice after TREK1 knockdown (n = 67–76 sections; ****p < 0.0001; unpaired t-test). d, Quantification of VGAT fluorescence intensity in 3xTg mice after TREK1 knockdown (n = 60–63 sections; ****p < 0.0001; unpaired t-test). e, Quantification of Excitatory/inhibitory (E/I) ratio, calculated as VGLUT1/VGAT intensity, is markedly elevated in TREK1 knockdown mice compared with vehicle injected controls (n = 3– 4; **p < 0.01; unpaired t-test). f, Representative immunofluorescence images demonstrating enhanced Aβ deposition in the hippocampus of TREK1 knockdown 3xTg mice compared with vehicle-injected controls. g, Quantification of Aβ fluorescence intensity in 3xTg mice after TREK1 knockdown (n = 50 sections; *p < 0.05; unpaired t-test). h, Quantification showing a significant decrease in <t>MAP2</t> intensity in the hippocampus of 3xTg mice injected with TREK1 shRNA compared with scrambled (Sc) shRNA controls (n = 159–166 sections; ****p < 0.0001; unpaired t-test). i, Schematic representation illustrating the effects of TREK1 knockdown on excitatory/inhibitory balance. Data are expressed as mean ± SEM from 3–4 mice per group.
Rabbit Map2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+signalling+technology+8707/MAP2+XP+Rabbit+mAb/bio_rxiv__2025__10__16__682816-189-32-35
Average 96 stars, based on 1 article reviews
rabbit map2 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


a, Representative immunofluorescence images showing increased VGLUT1 intensity in the hippocampus of 3xTg mice 15 days after intrahippocampal injection with TREK1 shRNA lentivirus compared with vehicle-injected controls. b, Representative images showing decreased VGAT intensity under the same TREK1 knockdown conditions. c, Quantification of VGLUT1 fluorescence intensity in 3xTg mice after TREK1 knockdown (n = 67–76 sections; ****p < 0.0001; unpaired t-test). d, Quantification of VGAT fluorescence intensity in 3xTg mice after TREK1 knockdown (n = 60–63 sections; ****p < 0.0001; unpaired t-test). e, Quantification of Excitatory/inhibitory (E/I) ratio, calculated as VGLUT1/VGAT intensity, is markedly elevated in TREK1 knockdown mice compared with vehicle injected controls (n = 3– 4; **p < 0.01; unpaired t-test). f, Representative immunofluorescence images demonstrating enhanced Aβ deposition in the hippocampus of TREK1 knockdown 3xTg mice compared with vehicle-injected controls. g, Quantification of Aβ fluorescence intensity in 3xTg mice after TREK1 knockdown (n = 50 sections; *p < 0.05; unpaired t-test). h, Quantification showing a significant decrease in MAP2 intensity in the hippocampus of 3xTg mice injected with TREK1 shRNA compared with scrambled (Sc) shRNA controls (n = 159–166 sections; ****p < 0.0001; unpaired t-test). i, Schematic representation illustrating the effects of TREK1 knockdown on excitatory/inhibitory balance. Data are expressed as mean ± SEM from 3–4 mice per group.

Journal: bioRxiv

Article Title: Hyperexcitability in Alzheimer’s Disease triggers a compensatory neuroprotective response via TREK1

doi: 10.1101/2025.10.16.682816

Figure Lengend Snippet: a, Representative immunofluorescence images showing increased VGLUT1 intensity in the hippocampus of 3xTg mice 15 days after intrahippocampal injection with TREK1 shRNA lentivirus compared with vehicle-injected controls. b, Representative images showing decreased VGAT intensity under the same TREK1 knockdown conditions. c, Quantification of VGLUT1 fluorescence intensity in 3xTg mice after TREK1 knockdown (n = 67–76 sections; ****p < 0.0001; unpaired t-test). d, Quantification of VGAT fluorescence intensity in 3xTg mice after TREK1 knockdown (n = 60–63 sections; ****p < 0.0001; unpaired t-test). e, Quantification of Excitatory/inhibitory (E/I) ratio, calculated as VGLUT1/VGAT intensity, is markedly elevated in TREK1 knockdown mice compared with vehicle injected controls (n = 3– 4; **p < 0.01; unpaired t-test). f, Representative immunofluorescence images demonstrating enhanced Aβ deposition in the hippocampus of TREK1 knockdown 3xTg mice compared with vehicle-injected controls. g, Quantification of Aβ fluorescence intensity in 3xTg mice after TREK1 knockdown (n = 50 sections; *p < 0.05; unpaired t-test). h, Quantification showing a significant decrease in MAP2 intensity in the hippocampus of 3xTg mice injected with TREK1 shRNA compared with scrambled (Sc) shRNA controls (n = 159–166 sections; ****p < 0.0001; unpaired t-test). i, Schematic representation illustrating the effects of TREK1 knockdown on excitatory/inhibitory balance. Data are expressed as mean ± SEM from 3–4 mice per group.

Article Snippet: Primary antibodies- chicken MAP2 (1:1000, Invitrogen, PA1-10005), rabbit TREK1 (1:100, Alomone Labs, #APC-047), Rabbit CTCF (1:100, Invitrogen, #MA5-88115), Mouse AC1 (1:50, Santa Cruz, #SC- 365350), Mouse AC8 (1:50, Santa Cruz, #SC-377442) and rabbit MAP2 (1:150, Cell Signalling Technology, #8707S) were diluted in PBST and applied overnight at 4°C.

Techniques: Immunofluorescence, Injection, shRNA, Knockdown, Fluorescence